Dharma Sansad: Togadia asks govt to control mosques and churches instead of temples

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Mandya, Jul 24: Pressing for a total ban on stone mining and quarrying in and around the villages surrounding Krishna Raja Sagar Dam in the District, many organisations have called for Mandya bandh on July 29.

The bandh has been supported by Raitha Sangha, Karunada Sevakara Sanghatane, Auto Drivers Association, Jaya Karnataka, Bharatiya Samvidhana Hitharakshana Vedike, Sugarcane Growers Association, Vokkaligara Seva Trust and Dalita Sangarsh Samiti (Krishnappa faction).

The activists said that the State Government must immediately take steps and permanently ban mining in 20 km radius around KRS as continuous blasting for stones is causing grave danger to the structure.

Kota, May 9: Karnataka Yakshagana Academy has come to the rescue of artists in distress due to cancellation of all Yakshagana festivals following coronavirus outbreak and clamping of lock-down.

The academy spends lakh of rupees every year from the money sanctioned to it on training new artists, performances and documentation. However, no such activity was undertaken due to COVID-19. Hence, the academy is discussing to transfer a large amount of money to Yakshagana artists as emergency aid, Academy President Prof M A Hegde said here.

In a statement issued here on Saturday, he said that along with this aid the donations by the public and Yakshagana admirers too could be given to the artists.